HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplementary Material Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gabriel, G. Articles by Klenk, H.-D. Search for Related Content PubMed PubMed Citation Articles by Gabriel, G. Articles by Klenk, H.-D. Agricola Articles by Gabriel, G. Articles by Klenk, H.-D.

Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7 virus

Gülsah Gabriel^1,

¹ Institute of Virology, Philipps University Marburg, Germany
² AVI BioPharma Inc., Corvallis, OR, USA

Correspondence
Gülsah Gabriel
guelsah.gabriel{at}path.ox.ac.uk

Peptide-conjugated phosphorodiamidate morpholino oligomers (PPMO) are single-stranded nucleic acid-analogue antisense agents that enter cells readily and can reduce gene expression by steric blocking of complementary RNA (cRNA) sequences. Here, we tested a panel of PPMO designed to target conserved sequences in the RNA genome segments encoding polymerase subunits of a highly pathogenic mouse-adapted influenza A virus (SC35M; H7N7). Three PPMO, targeting the translation start site region of PB1 or NP mRNA or the 3'-terminal region of NP viral RNA (vRNA), potently inhibited virus replication in MDCK cells. Primer extension assays showed that treatment with any of the effective PPMO led to markedly reduced levels of mRNA, cRNA and vRNA. Initially, the potential toxicity of a range of intranasally administered PPMO doses was evaluated, by measuring their effect on body weight of uninfected mice. Subsequently, a non-toxic dosing regimen was used to investigate the effect of various PPMO on SC35M infection in a mouse model. Mice administered intranasal treatment of PPMO targeting the PB1-AUG region or NP vRNA, at 3 µg per dose, given once 3 h before and once 2 days after intranasal infection with 10xLD₅₀ of SC35M, showed a 2 log₁₀ reduction of viral titre in the lungs and 50 % survival for the 16 day duration of the experiment, whereas the NP-AUG-targeted PPMO treatment resulted in 30 % survival of an otherwise lethal infection. These data suggest that PPMO provide a useful reagent to investigate influenza virus molecular biology and may constitute a therapeutic strategy against highly pathogenic influenza viruses.

Present address: Sir William Dunn School of Pathology, University of Oxford, UK.

Supplementary material is available with the online version of this paper.

This article has been cited by other articles:

				G. Gabriel, K. Klingel, O. Planz, K. Bier, A. Herwig, M. Sauter, and H.-D. Klenk Spread of Infection and Lymphocyte Depletion in Mice Depends on Polymerase of Influenza Virus Am. J. Pathol., September 1, 2009; 175(3): 1178 - 1186. [Abstract] [Full Text] [PDF]

				V. Krahling, D. A. Stein, M. Spiegel, F. Weber, and E. Muhlberger Severe Acute Respiratory Syndrome Coronavirus Triggers Apoptosis via Protein Kinase R but Is Resistant to Its Antiviral Activity J. Virol., March 1, 2009; 83(5): 2298 - 2309. [Abstract] [Full Text] [PDF]

				D. A. Stein, C. Y.-H. Huang, S. Silengo, A. Amantana, S. Crumley, R. E. Blouch, P. L. Iversen, and R. M. Kinney Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus J. Antimicrob. Chemother., September 1, 2008; 62(3): 555 - 565. [Abstract] [Full Text] [PDF]